News Sentiment

A1LN34 sentiment intelligence

Alnylam Pharmaceuticals, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 46 Balanced news tone 10 relevant articles
Exchange SAO Brazil
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 76.96 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

88/100 classification confidence.

Company focus 10

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.7% over one week, +6.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 88/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend inactive 6.1% over four weeks
Fair value 5.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 9
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 10
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Investing.com 6
Business Wire 2
Stock Titan 1
Bloomberg.com 1

Event Lens

What the news is about

Classified themes
Market update 8
Earnings 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-10 of 10